

Edgar Filing: BIOTRANSPLANT INC - Form 8-K

BIOTRANSPLANT INC
Form 8-K
August 02, 2002

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 22, 2002

BioTransplant Incorporated

(Exact name of registrant as specified in its charter)

Delaware

000-28324

04-3119555

(State or other jurisdiction
of incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

Building 75, Third Avenue
Charlestown Navy Yard
Charlestown, MA

02129

(Address of principal
executive offices)

(Zip Code)

Registrant's telephone number, including area code: (617) 241-5200

N/A

(Former name or former address, if changed since last report)

Item 5. Other Events.

On July 22, 2002, BioTransplant Incorporated (the "Company") issued a press release announcing that its Board of Directors had elected Donald B. Hawthorne to the position of President and Chief Executive Officer of the Company. See the press release attached hereto as Exhibit 99.1.

On July 29, 2002, the Company issued a press release announcing a restructuring plan, which includes a reduction in workforce, intended to

Edgar Filing: BIOTRANSPLANT INC - Form 8-K

streamline the Company's operations around a new strategic focus. See the press release attached hereto as Exhibit 99.2.

Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.

(c) Exhibits.

See Exhibit Index attached hereto.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August 2, 2002

BIOTRANSPLANT INCORPORATED

By: /s/ Donald B. Hawthorne

Donald B. Hawthorne
President and Chief
Executive Officer

EXHIBIT INDEX

Exhibit No.

Exhibit

Exhibit 99.1

Press Release dated July 22, 2002

Exhibit 99.2

Press Release dated July 29, 2002